Last reviewed · How we verify
DHA-PP
At a glance
| Generic name | DHA-PP |
|---|---|
| Also known as | Duo-Cotecxin |
| Sponsor | Institut Pasteur, Cambodia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment (PHASE2,PHASE3)
- Safety and Tolerability of Low Dose Primaquine (PHASE4)
- Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA-PP CI brief — competitive landscape report
- DHA-PP updates RSS · CI watch RSS
- Institut Pasteur, Cambodia portfolio CI